newsfilter
← Latest News
PR Newswire·

TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026

Poster highlights durable disease control, acceptable tolerability and exploratory evidence of treatment-associated antitumor immune activity in patients with advanced solid tumorsBOSTON, Oct. 26, 2026 /PRNewswire/ --